Biotech Watch

complete, accurate, and up-to-date information on publicly traded biotechnology companies

Biotech Watch Home
 

Welcome to Biotech Watch

BiotechWatch provides unbiased, accurate, and timely information concerning the biotech industry, with the goal of creating a web-based community for the exchange of ideas around biotech investing and drug development.

We offer the following three levels of access to biotech information:

  • Premium Access
  • Our Premium database offers an in-depth coverage of biotechnology companies in the sector, giving users the ability to search and sort based on more than 20 parameters including cash on hand, burn rate, clinical trial status, pending milestones, and medical indication. The database is continuously updated every 20 minutes to provide you with complete, most accurate, and up-to-date information.




    More Details

  • Clinical Trial Access
  • Our Clinical Trial database offers disease-specific and biotechnology sector-wide clinical trial information. This database allows the user to point and click on over 200 diseases or 20 medical specialties to identify biotech products under development and their associated biotech companies. If you're looking for the fastest and safest way to find treatments, the BiotechWatch Clinical Trial database allows you to narrow down companies based on their clinical trials.

    More Details

  • Customized Access
  • Our Customized Access searches the entire publicly traded biotechnology sector, accessing clinical and financial information across 500 companies via a simple point and click. Searches include biotech companies selling at or near cash, biotech companies with upcoming clinical or regulatory milestones in the next twelve months, biotech companies selling at 52 week lows or highs, and many more.




    More Details

In addition, we offer the following unique services:
  • Knowledge Base - We provide access to a comprehensive library of documents and resources provided by the National Institutes of Health.
  • Forum - We provide an easy and efficient means for biotech investors to exchange witty ideas in an effort to maximize their profitability. The Forum is a place where new and compelling biotech investments and significant advances in biotechnology are discussed in detail.
  • Real Time Vote Tally
  • Cephalon's Treanda has a 10/31/2008 PDUFA date. Will the FDA approve Treanda for non-Hodgkin’s Lymphoma?
  • Answer
  • Votes
  • Yes, full market approval
  • 1
  • No, FDA will not approve
  • 1
  • Will receive approvable letter
  • 2
 
  • Biotech News
Cepheid announced the release of Xpert vanA/vanB as a European CE IVD Mark product under the European Directive on In Vitro Diagnostic Medical Devices. The... Peregrine Pharmaceuticals completed enrollment in the first stage of a Phase II trial of bavituximab in combination with chemotherapy in patients with advanced breast cancer.... Pluristem Therapeutics announced it had been appointed to the Advisory Board of The Stem Cell Partnering Series. The Stem Cell Partnering Series is a not-for-profit... AtheroGenics announced that it has consented to the Involuntary Chapter 7 Petition filed against the Company on September 15, 2008 in the U.S. Bankruptcy Court... Myriad Genetics has acquired the exclusive North American license to specific application of novel proprietary technology used to perform pharmacokinetic analysis of therapeutic drugs in... Vical and AnGes MG signed a non-binding Letter of Intent indicating their mutual interest to license the development and marketing rights for Vical's pandemic influenza... Fluidigm Corporation and BIOKE, a licensed distributor for the company, announced that Enza Zaden, one of the world's leading suppliers of high-quality vegetable seeds for... Bavarian Nordic has now evaluated the mature phase II data from the therapeutic prostate cancer vaccine candidate PROSTVAC that had been obtained as part of... Antisoma, The Institute of Cancer Research (The Institute) and Cancer Research Technology (CRT) announced a collaboration and licensing agreement under which Antisoma has acquired rights... Genentech and Biogen Idec announced that a global Phase III study of Rituxan (rituximab) in combination with fludarabine and cyclophosphamide chemotherapy met its primary endpoint... Poniard Pharmaceuticals announced that it has exercised its option to draw down a $10.0 million second tranche, which represents the balance of the Company's $27.6... Biolex Therapeutics announced the closing of a $60 million Series D financing led by Clarus Ventures, a leading biotechnology investor, with OrbiMed Advisors participating as... Micromet closed its previously announced $40 million private placement financing. Participants include leading biotechnology investors Index Ventures Growth, Abingworth, DAFNA Capital Management, LLC, and Merlin...